Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ZVRA vs CAPR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ZVRA Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 10–0 Matrix Metrics)

ZVRA Overall Winner 6-Pillar Tally: ZVRA 5 – 1 CAPR Matrix Metrics: ZVRA 10 – 0 CAPR

As of Nov 16, 2026, Zevra Therapeutics, Inc. (ZVRA) is the stronger overall head-to-head candidate over Capricor Therapeutics Inc (CAPR) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZVRA carries a Unified Composite Score of 49.4/100 (HOLD) at $9.31 (9.3x Forward P/E, 31.5% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: ZVRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.9); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ZVRA vs CAPR
ZVRA NASDAQ Head-to-Head Winner
Zevra Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$9.31
+2.53% 1D
Market Cap $664.1M
TTM Revenue $148M
Forward P/E 9.3x
Beta / 30D Vol 1.18β · 95% Vol
Unified Composite Score
49.4 / 100 HOLD
Tech 37.0 Fund 53.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.4%), weak momentum, RSI 39
RSI-14: 38.9 · SMA20: $10.53 · SMA50: $10.92
CAPR NASDAQ
Capricor Therapeutics Inc
Pharmaceutical Preparations
$8.47
-11.12% 1D
Market Cap $595.4M
TTM Revenue $11M
Forward P/E 78.7x
Beta / 30D Vol 1.52β · 152% Vol
Unified Composite Score
28.0 / 100 SELL
Tech 50.0 Fund 37.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 51
RSI-14: 51.4 · SMA20: $7.79 · SMA50: $8.08

6-Pillar Scorecard Institutional Category Breakdown (ZVRA 5 – 1 CAPR)

Columns: Metric · ZVRA · CAPR
1. Valuation Multiples ZVRA
Forward P/E 9.3x 78.7x
Trailing P/E 9.7x 78.7x
PEG Ratio 10.67x 0.38x
EV / Revenue 3.7x 57.8x
2. Growth & Scale ZVRA
Revenue Growth (YoY) +44.9% -7.9%
Earnings Growth (YoY) -88.4% +0.0%
TTM Revenue (USD) $148M $11M
Market Cap $664.1M $595.4M
3. Profitability & Quality ZVRA
Gross Margin 95.4% N/A
Operating Margin 31.5% 0.0%
Net Profit Margin 52.8% 0.0%
Return on Equity (ROE) 41.9% -100.5%
4. Balance Sheet & Cash Flow ZVRA
Cash Generation (TTM) $38M -$146M
Cash Flow Margin 25.9% N/A
Net Cash / Leverage $121M Net Cash $48M Net Debt (0.44x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CAPR
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 71.7% (14th %ile) 637.1% (89th %ile)
Put/Call OI Skew 1.62x (Put-Skewed) 1.57x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat ZVRA
OpEx & R&D Intensity 63.9% of Rev ($94M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ZVRA (10) vs CAPR (0)
Institutional Metric ZVRA CAPR Criterion Row Edge
Market Capitalization
Scale
$664.1M $595.4M Larger Scale ZVRA
Trailing P/E Ratio
Valuation
9.7x 78.7x Lower Multiple ZVRA
Forward P/E Ratio
Valuation
9.3x 78.7x Lower Multiple ZVRA
Revenue Growth (YoY)
Growth
+44.9% -7.9% Higher Growth ZVRA
Operating Margin (TTM)
Profitability
31.5% 0.0% Higher Margin ZVRA
Net Profit Margin
Profitability
52.8% 0.0% Higher Margin ZVRA
Return on Equity (ROE)
Capital Efficiency
41.9% -100.5% Higher ROE ZVRA
52-Week Range Position
Momentum
18% ($8–$15) 15% ($3–$40) Stronger Trend ZVRA
Beta / 30D Volatility
Risk Regime
1.18β · 95% Vol 1.52β · 152% Vol Lower Realized Risk ZVRA
Unified Institutional Score
Composite Signal
49.4 / 100 (HOLD) 28.0 / 100 (SELL) Higher Composite ZVRA
Trailing 12M Revenue (USD)
Operating Scale
$148M $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
95.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
10.67x PEG · 3.7x EV/Rev 0.38x PEG · 57.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$38M ($121M Net Cash) -$146M ($48M Net Debt (0.44x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAPR +32.57 pp
ZVRA: -6.34% · CAPR: +26.23%
3M Horizon CAPR +39.16 pp
ZVRA: -19.53% · CAPR: +19.63%
6M Horizon ZVRA +55.14 pp
ZVRA: -15.44% · CAPR: -70.58%
1Y Horizon CAPR +45.92 pp
ZVRA: +0.87% · CAPR: +46.79%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ZVRA Revenue CAPR Revenue ZVRA Op. Margin CAPR Op. Margin Margin Leader
FY2018 N/A $0M N/A -917.0% CAPR
FY2019 $10M $0M -158.4% -769.5% ZVRA
FY2020 $10M $0M -42.2% -4412.6% ZVRA
FY2021 $30M $0M 27.0% -8549.9% ZVRA
FY2022 $10M $0M -418.9% -1163.9% ZVRA
FY2023 $30M $30M -180.6% -95.6% CAPR
FY2024 $20M $20M -368.5% -191.1% CAPR
FY2025 $110M N/A -59.1% N/A ZVRA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ZVRA BREAKDOWN
111d in phase · OBV DISTRIBUTION
Current IV 71.7%
IV Percentile 14th %ile
Put/Call OI Skew 1.62x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact ZVRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CAPR CONSOLIDATION
56d in phase · OBV ACCUMULATION
Current IV 637.1%
IV Percentile 89th %ile
Put/Call OI Skew 1.57x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CAPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ZVRA Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $664.1M market capitalization and 31.5% operating margin.
OpEx & R&D Reinvestment 63.9% of Rev ($94M)
90D Engineering Disclosures 0 Published
CAPR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $595.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ZVRA vs CAPR Key Questions & Quantitative Answers

As of Nov 16, 2026, Zevra Therapeutics, Inc. (ZVRA) is the stronger overall head-to-head candidate over Capricor Therapeutics Inc (CAPR) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZVRA carries a Unified Composite Score of 49.4/100 (HOLD) at $9.31 (9.3x Forward P/E, 31.5% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: ZVRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.9); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ZVRA leads the Growth & Scale pillar: ZVRA posts +44.9% YoY revenue growth and -88.4% YoY earnings growth on $148M TTM revenue (95.4% gross margin, 31.5% operating margin), compared with CAPR at -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ZVRA cumulative revenue shifted +1000.0% while CAPR shifted -33.3%. In operating R&D and SG&A reinvestment, ZVRA deploys 63.9% of Rev ($94M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAPR.

ZVRA screens cheaper on headline valuation multiples. ZVRA trades at 9.3x Forward P/E, 9.7x Trailing P/E, 10.67x PEG, and 3.7x EV/Revenue (25.9% FCF margin), whereas CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZVRA (41.9% ROE) versus CAPR (-100.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ZVRA carries 71.7% implied volatility (14th %ile, Compressed (<25th %ile)), a 1.62x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.18β · 95% Vol realized risk). By comparison, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.